The ultimate objective of this research is to provide viable clinical agents useful as sensitizers in the photodynamic therapy (PDT) of cancer.
One aim of the proposed research is to design, synthesize, and evaluate new sensitizers for PDT that: 1) are selectively retained in tumors, 2) display no long-term skin photosensitivity, 3) have high quantum yields for the cytotoxic event, 4) deplete glutathione levels during PDT, and 5) absorb longer wavelengths of light where light penetration into tissue is optimal. These desirable features can be obtained by replacing oxygen or sulfur in the sensitizer chromophore with the heavy atoms selenium or tellurium. Selenium and tellurium analogues of both the anticarcinoma agent AA1 and the rhodamine dyes will be prepared and evaluated for their spectral, chemical, and photophysical properties, which include n-octanol water partition coefficients, quantum yields for singlet oxygen generation, pH-sensitive hydrolysis rates, reactivity with singlet oxygen, and rates of reaction of oxidized dyes with glutathione. The biological activity of the new drugs with appropriate spectral, chemical, and photophysical properties will be evaluated in vitro against several cancer cell lines to determine: 1) uptake of the dyes, 2) dark and phototoxicities, and 3) mechanisms of phototoxicity. Isolated mitochondrial suspensions will also be used to evaluate mechanisms of phototoxicity. Sensitizers that show promise in the in vitro studies or appropriately modified new derivatives will be evaluated in vivo using a rat mammary tumor model for therapeutic efficacy, pharmacokinetic studies of dye distribution and retention in normal and cancer tissues, and effects on cellular glutathione levels. PDT with the selenopyrylium dye KL-Se, which shows no toxicity at 29 mg (62 umol)/ kg and is selectively retained by tumors, will be optimized to improve upon the 300 percent increase in tumor doubling time (relative to untreated controls) already observed in initial PDT studies with KL-Se.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069155-07
Application #
6708903
Study Section
Metallobiochemistry Study Section (BMT)
Program Officer
Stone, Helen B
Project Start
1996-09-01
Project End
2005-03-31
Budget Start
2004-04-01
Budget End
2005-03-31
Support Year
7
Fiscal Year
2004
Total Cost
$215,645
Indirect Cost
Name
State University of New York at Buffalo
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Wagner, Stephen J; Skripchenko, Andrey; Donnelly, David J et al. (2005) Chalcogenoxanthylium photosensitizers for the photodynamic purging of blood-borne viral and bacterial pathogens. Bioorg Med Chem 13:5927-35
Detty, Michael R; Gibson, Scott L; Hilf, Russell (2004) Comparison of the dark and light-induced toxicity of thio and seleno analogues of the thiopyrylium dye AA1. Bioorg Med Chem 12:2589-96
Detty, Michael R; Prasad, Paras N; Donnelly, David J et al. (2004) Synthesis, properties, and photodynamic properties in vitro of heavy-chalcogen analogues of tetramethylrosamine. Bioorg Med Chem 12:2537-44
Detty, Michael R; Gibson, Scott L; Wagner, Stephen J (2004) Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 47:3897-915
Brennan, Nancy K; Donnelly, David J; Detty, Michael R (2003) Selenoxanthones via directed metalations in 2-arylselenobenzamide derivatives. J Org Chem 68:3344-7
You, Youngjae; Gibson, Scott L; Hilf, Russell et al. (2003) Water soluble, core-modified porphyrins. 3. Synthesis, photophysical properties, and in vitro studies of photosensitization, uptake, and localization with carboxylic acid-substituted derivatives. J Med Chem 46:3734-47
Brennan, Nancy K; Hall, Jonathan P; Davies, Sherry R et al. (2002) In vitro photodynamic properties of chalcogenopyrylium analogues of the thiopyrylium antitumor agent AA1. J Med Chem 45:5123-35
Stilts, C E; Nelen, M I; Hilmey, D G et al. (2000) Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. J Med Chem 43:2403-10
Leonard, K A; Hall, J P; Nelen, M I et al. (2000) A selenopyrylium photosensitizer for photodynamic therapy related in structure to the antitumor agent AA1 with potent in vivo activity and no long-term skin photosensitization. J Med Chem 43:4488-98
Leonard, K A; Nelen, M I; Anderson, L T et al. (1999) 2,4,6-triarylchalcogenopyrylium dyes related in structure to the antitumor agent AA1 as in vitro sensitizers for the photodynamic therapy of cancer. J Med Chem 42:3942-52

Showing the most recent 10 out of 12 publications